Peripheral blood biomarkers of solid tumor angiogenesis in dogs: A polychromatic flow cytometry pilot study

R. Timothy Bentley, Julie A. Mund, Karen Pollok, Michael O. Childress, Jamie Case

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A subset of peripheral blood hematopoietic stem and progenitor cells of bone marrow origin is elevated in humans with solid cancers before treatment and declines with therapy. This biomarker of angiogenesis is not specific to tumor type and has great potential in the objective assessment of treatment response in clinical trials. This pilot study was designed to develop a biomarker of neoangiogenesis in dogs for the diagnosis of cancer, the measurement of treatment response, and the provision of objective data in clinical trials. Polychromatic flow cytometry was used to quantify two subsets of circulating hematopoietic stem and progenitor cells in dogs with spontaneous solid tumors before (n= 8) and after (n= 3) treatment, and normal controls (n= 6).Pro-angiogenic peripheral blood cells of bone marrow origin were detected in all eight cases and the six normal controls; however, there was no statistically significant difference between the two groups. Interestingly, an apparent decline in pro-angiogenic cells was observed after treatment. Bone marrow derived hematopoietic cells appear to contribute to tumor angiogenesis in dogs, as has been previously reported in humans. While the methodology for pro-angiogenic cell quantification in a small number of dogs in the current study did not result in a significant difference from normal controls, an optimized canine polychromatic flow cytometry protocol holds great promise in the development of a canine cancer model and for the objective measurements of treatment response in clinical trials.

Original languageEnglish
Pages (from-to)236-240
Number of pages5
JournalVeterinary Journal
Volume196
Issue number2
DOIs
StatePublished - May 2013

Fingerprint

Tumor Biomarkers
angiogenesis
flow cytometry
biomarkers
Flow Cytometry
Dogs
Hematopoietic Stem Cells
neoplasms
dogs
blood
bone marrow
clinical trials
Neoplasms
Bone Marrow
Clinical Trials
Canidae
Biomarkers
cells
blood cells
Blood Cells

Keywords

  • Angiogenesis
  • Biomarker
  • Cancer
  • Dog
  • Polychromatic flow cytometry

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

Peripheral blood biomarkers of solid tumor angiogenesis in dogs : A polychromatic flow cytometry pilot study. / Bentley, R. Timothy; Mund, Julie A.; Pollok, Karen; Childress, Michael O.; Case, Jamie.

In: Veterinary Journal, Vol. 196, No. 2, 05.2013, p. 236-240.

Research output: Contribution to journalArticle

Bentley, R. Timothy ; Mund, Julie A. ; Pollok, Karen ; Childress, Michael O. ; Case, Jamie. / Peripheral blood biomarkers of solid tumor angiogenesis in dogs : A polychromatic flow cytometry pilot study. In: Veterinary Journal. 2013 ; Vol. 196, No. 2. pp. 236-240.
@article{7f9c1a151c814c1a976f8ae071fc052e,
title = "Peripheral blood biomarkers of solid tumor angiogenesis in dogs: A polychromatic flow cytometry pilot study",
abstract = "A subset of peripheral blood hematopoietic stem and progenitor cells of bone marrow origin is elevated in humans with solid cancers before treatment and declines with therapy. This biomarker of angiogenesis is not specific to tumor type and has great potential in the objective assessment of treatment response in clinical trials. This pilot study was designed to develop a biomarker of neoangiogenesis in dogs for the diagnosis of cancer, the measurement of treatment response, and the provision of objective data in clinical trials. Polychromatic flow cytometry was used to quantify two subsets of circulating hematopoietic stem and progenitor cells in dogs with spontaneous solid tumors before (n= 8) and after (n= 3) treatment, and normal controls (n= 6).Pro-angiogenic peripheral blood cells of bone marrow origin were detected in all eight cases and the six normal controls; however, there was no statistically significant difference between the two groups. Interestingly, an apparent decline in pro-angiogenic cells was observed after treatment. Bone marrow derived hematopoietic cells appear to contribute to tumor angiogenesis in dogs, as has been previously reported in humans. While the methodology for pro-angiogenic cell quantification in a small number of dogs in the current study did not result in a significant difference from normal controls, an optimized canine polychromatic flow cytometry protocol holds great promise in the development of a canine cancer model and for the objective measurements of treatment response in clinical trials.",
keywords = "Angiogenesis, Biomarker, Cancer, Dog, Polychromatic flow cytometry",
author = "Bentley, {R. Timothy} and Mund, {Julie A.} and Karen Pollok and Childress, {Michael O.} and Jamie Case",
year = "2013",
month = "5",
doi = "10.1016/j.tvjl.2012.09.002",
language = "English",
volume = "196",
pages = "236--240",
journal = "Veterinary Journal",
issn = "1090-0233",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Peripheral blood biomarkers of solid tumor angiogenesis in dogs

T2 - A polychromatic flow cytometry pilot study

AU - Bentley, R. Timothy

AU - Mund, Julie A.

AU - Pollok, Karen

AU - Childress, Michael O.

AU - Case, Jamie

PY - 2013/5

Y1 - 2013/5

N2 - A subset of peripheral blood hematopoietic stem and progenitor cells of bone marrow origin is elevated in humans with solid cancers before treatment and declines with therapy. This biomarker of angiogenesis is not specific to tumor type and has great potential in the objective assessment of treatment response in clinical trials. This pilot study was designed to develop a biomarker of neoangiogenesis in dogs for the diagnosis of cancer, the measurement of treatment response, and the provision of objective data in clinical trials. Polychromatic flow cytometry was used to quantify two subsets of circulating hematopoietic stem and progenitor cells in dogs with spontaneous solid tumors before (n= 8) and after (n= 3) treatment, and normal controls (n= 6).Pro-angiogenic peripheral blood cells of bone marrow origin were detected in all eight cases and the six normal controls; however, there was no statistically significant difference between the two groups. Interestingly, an apparent decline in pro-angiogenic cells was observed after treatment. Bone marrow derived hematopoietic cells appear to contribute to tumor angiogenesis in dogs, as has been previously reported in humans. While the methodology for pro-angiogenic cell quantification in a small number of dogs in the current study did not result in a significant difference from normal controls, an optimized canine polychromatic flow cytometry protocol holds great promise in the development of a canine cancer model and for the objective measurements of treatment response in clinical trials.

AB - A subset of peripheral blood hematopoietic stem and progenitor cells of bone marrow origin is elevated in humans with solid cancers before treatment and declines with therapy. This biomarker of angiogenesis is not specific to tumor type and has great potential in the objective assessment of treatment response in clinical trials. This pilot study was designed to develop a biomarker of neoangiogenesis in dogs for the diagnosis of cancer, the measurement of treatment response, and the provision of objective data in clinical trials. Polychromatic flow cytometry was used to quantify two subsets of circulating hematopoietic stem and progenitor cells in dogs with spontaneous solid tumors before (n= 8) and after (n= 3) treatment, and normal controls (n= 6).Pro-angiogenic peripheral blood cells of bone marrow origin were detected in all eight cases and the six normal controls; however, there was no statistically significant difference between the two groups. Interestingly, an apparent decline in pro-angiogenic cells was observed after treatment. Bone marrow derived hematopoietic cells appear to contribute to tumor angiogenesis in dogs, as has been previously reported in humans. While the methodology for pro-angiogenic cell quantification in a small number of dogs in the current study did not result in a significant difference from normal controls, an optimized canine polychromatic flow cytometry protocol holds great promise in the development of a canine cancer model and for the objective measurements of treatment response in clinical trials.

KW - Angiogenesis

KW - Biomarker

KW - Cancer

KW - Dog

KW - Polychromatic flow cytometry

UR - http://www.scopus.com/inward/record.url?scp=84878898579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878898579&partnerID=8YFLogxK

U2 - 10.1016/j.tvjl.2012.09.002

DO - 10.1016/j.tvjl.2012.09.002

M3 - Article

C2 - 23063489

AN - SCOPUS:84878898579

VL - 196

SP - 236

EP - 240

JO - Veterinary Journal

JF - Veterinary Journal

SN - 1090-0233

IS - 2

ER -